Evidence map›Paper›PMID 33978742›Full record

ArticleBrain : a journal of neurology2021

The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.

Emma Biondetti, Mathieu D Santin, Romain Valabrègue, Graziella Mangone, Rahul Gaurav, Nadya Pyatigorskaya, Matthew Hutchison, Lydia Yahia-Cherif, Nicolas Villain, Marie-Odile Habert and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 1 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 1 synthesis or guideline pooled it, 168 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. In Vivo Mapping of Catecholaminergic Loss and Iron Deposition in Huntington's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  15. Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Emma BiondettiSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.ORCID 0000-0001-6727-0935
Mathieu D SantinSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
Romain ValabrègueSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
Graziella MangoneSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
Rahul GauravSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.ORCID 0000-0001-9983-5873
Nadya PyatigorskayaSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.ORCID 0000-0002-2070-1299
Matthew HutchisonBiogen Inc., Cambridge, MA 02142, USA.
Lydia Yahia-CherifSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
Nicolas VillainSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
Marie-Odile HabertAssistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine, 75013 Paris, France.
Isabelle ArnulfSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.ORCID 0000-0002-2240-2516
Smaranda Leu-SemenescuAssistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Sleep Disorder Unit, 75013 Paris, France.ORCID 0000-0001-9556-4527
Pauline DodetAssistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Sleep Disorder Unit, 75013 Paris, France.
Miquel VilaNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR)-Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED)-Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona (UAB)-Catalan Institution for Research and Advanced Studies (ICREA), 08010 Barcelona, Spain.
Jean-Christophe CorvolSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
Marie VidailhetSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
Stéphane LehéricySorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
Centre National de la Recherche Scientifique · FRSorbonne Université · FRBiogen (United States) · USInstitució Catalana de Recerca i Estudis Avançats · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Parkinson's disease, there is a progressive reduction in striatal dopaminergic function, and loss of neuromelanin-containing dopaminergic neurons and increased iron deposition in the substantia nigra. We tested the hypothesis of a relationship between impairment of the dopaminergic system and changes in the iron metabolism. Based on imaging data of patients with prodromal and early clinical Parkinson's disease, we assessed the spatiotemporal ordering of such changes and relationships in the sensorimotor, associative and limbic territories of the nigrostriatal system. Patients with Parkinson's disease (disease duration < 4 years) or idiopathic REM sleep behaviour disorder (a prodromal form of Parkinson's disease) and healthy controls underwent longitudinal examination (baseline and 2-year follow-up). Neuromelanin and iron sensitive MRI and dopamine transporter single-photon emission tomography were performed to assess nigrostriatal levels of neuromelanin, iron, and dopamine. For all three functional territories of the nigrostriatal system, in the clinically most and least affected hemispheres separately, the following was performed: cross-sectional and longitudinal intergroup difference analysis of striatal dopamine and iron, and nigral neuromelanin and iron; in Parkinson's disease patients, exponential fitting analysis to assess the duration of the prodromal phase and the temporal ordering of changes in dopamine, neuromelanin or iron relative to controls; and voxel-wise correlation analysis to investigate concomitant spatial changes in dopamine-iron, dopamine-neuromelanin and neuromelanin-iron in the substantia nigra pars compacta. The temporal ordering of dopaminergic changes followed the known spatial pattern of progression involving first the sensorimotor, then the associative and limbic striatal and nigral regions. Striatal dopaminergic denervation occurred first followed by abnormal iron metabolism and finally neuromelanin changes in the substantia nigra pars compacta, which followed the same spatial and temporal gradient observed in the striatum but shifted in time. In conclusion, dopaminergic striatal dysfunction and cell loss in the substantia nigra pars compacta are interrelated with increased nigral iron content.

Indexed as

AgedCohort StudiesCorpus StriatumDopamineFemaleHumansIronLongitudinal StudiesMagnetic Resonance ImagingMaleMelaninsMiddle AgedParkinson DiseaseProspective StudiesSubstantia NigraTime FactorsDopamineIronMelaninsneuromelanindopamine transporterimagingironneuromelaninParkinson’s disease

Identifiers

PMID33978742
PMCPMC8634084
OpenAlexW3163737948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.